| Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer M Xing, AS Alzahrani, KA Carson, D Viola, R Elisei, B Bendlova, L Yip, ... Jama 309 (14), 1493-1501, 2013 | 1036 | 2013 |
| Association between BRAF V600E mutation and recurrence of papillary thyroid cancer M Xing, AS Alzahrani, KA Carson, YK Shong, TY Kim, D Viola, R Elisei, ... Journal of clinical oncology 33 (1), 42, 2015 | 598 | 2015 |
| The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membrane G Riesco-Eizaguirre, P Gutierrez-Martinez, MA García-Cabezas, M Nistal, ... Endocrine-related cancer 13 (1), 257-269, 2006 | 477 | 2006 |
| The BRAFV600E oncogene induces transforming growth factor β secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer G Riesco-Eizaguirre, I Rodríguez, A De la Vieja, E Costamagna, ... Cancer research 69 (21), 8317-8325, 2009 | 330 | 2009 |
| A perspective view of sodium iodide symporter research and its clinical implications G Riesco-Eizaguirre, P Santisteban European Journal of Endocrinology 155 (4), 495-512, 2006 | 261 | 2006 |
| Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants X Shi, R Liu, F Basolo, R Giannini, X Shen, D Teng, H Guan, Z Shan, ... The Journal of Clinical Endocrinology 101 (1), 264-274, 2016 | 233 | 2016 |
| DNA methylation signatures identify biologically distinct thyroid cancer subtypes S Rodríguez-Rodero, AF Fernández, JL Fernández-Morera, ... The Journal of Clinical Endocrinology & Metabolism 98 (7), 2811-2821, 2013 | 149 | 2013 |
| New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy G Riesco-Eizaguirre, P Santisteban Endocrine-related cancer 14 (4), 957-977, 2007 | 149 | 2007 |
| Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients M Currás-Freixes, L Inglada-Pérez, V Mancikova, C Montero-Conde, ... Journal of medical genetics 52 (10), 647-656, 2015 | 122 | 2015 |
| Patient age–associated mortality risk is differentiated by BRAF V600E status in papillary thyroid cancer X Shen, G Zhu, R Liu, D Viola, R Elisei, E Puxeddu, L Fugazzola, ... Journal of Clinical Oncology 36 (5), 438, 2018 | 106 | 2018 |
| The miR-146b-3p/PAX8/NIS regulatory circuit modulates the differentiation phenotype and function of thyroid cells during carcinogenesis G Riesco-Eizaguirre, L Wert-Lamas, J Perales-Paton, A Sastre-Perona, ... Cancer research 75 (19), 4119-4130, 2015 | 103 | 2015 |
| The prognostic value of tumor multifocality in clinical outcomes of papillary thyroid cancer F Wang, X Yu, X Shen, G Zhu, Y Huang, R Liu, D Viola, R Elisei, ... The Journal of Clinical Endocrinology & Metabolism 102 (9), 3241-3250, 2017 | 101 | 2017 |
| BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment Y Huang, S Qu, G Zhu, F Wang, R Liu, X Shen, D Viola, R Elisei, ... JNCI: Journal of the National Cancer Institute 110 (4), 362-370, 2018 | 76 | 2018 |
| ENDOCRINE TUMOURS: Advances in the molecular pathogenesis of thyroid cancer: lessons from the cancer genome G Riesco-Eizaguirre, P Santisteban European journal of endocrinology 175 (5), R203-R217, 2016 | 69 | 2016 |
| MicroRNA deep-sequencing reveals master regulators of follicular and papillary thyroid tumors V Mancikova, E Castelblanco, E Pineiro-Yanez, J Perales-Paton, ... Modern Pathology 28 (6), 748-757, 2015 | 68 | 2015 |
| BRAF V600E confers male sex disease-specific mortality risk in patients with papillary thyroid cancer F Wang, S Zhao, X Shen, G Zhu, R Liu, D Viola, R Elisei, E Puxeddu, ... Journal of clinical oncology 36 (27), 2787, 2018 | 63 | 2018 |
| Impaired microRNA processing by DICER1 downregulation endows thyroid cancer with increased aggressiveness J Ramírez-Moya, L Wert-Lamas, G Riesco-Eizaguirre, P Santisteban Oncogene 38 (27), 5486-5499, 2019 | 57 | 2019 |
| ß-catenin signaling is required for RAS-driven thyroid cancer through PI3K activation A Sastre-Perona, G Riesco-Eizaguirre, MA Zaballos, P Santisteban Oncotarget 7 (31), 49435, 2016 | 52 | 2016 |
| BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma KJ Kim, SG Kim, J Tan, X Shen, D Viola, R Elisei, E Puxeddu, L Fugazzola, ... European Journal of Cancer 124, 161-169, 2020 | 47 | 2020 |
| BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer Y Tao, F Wang, X Shen, G Zhu, R Liu, D Viola, R Elisei, E Puxeddu, ... The Journal of Clinical Endocrinology & Metabolism 106 (11), 3228-3238, 2021 | 44 | 2021 |
